| Trial ID: | L0771 |
| Source ID: | TCTR20190118008
|
| Associated Drug: |
Canagliflozin
|
| Title: |
Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholic fatty liver disease: A double blind randomized controlled trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic fatty liver disease <br>Non-alcoholic Fatty Liver Disease<br>Obesity <br>Canagliflozin ;Non-alcoholic Fatty Liver Disease<br>Obesity <br>Canagliflozin
|
| Interventions: |
Patients will be prescribed with 1 tab of canagliflozin (100 mg) or once daily for 24 weeks.<br>Patients will also be encouraged to reduce 500-1000 calories from daily intake and have moderate intensity exercise at least 150 minutes per week. ,Patient
|
| Outcome Measures: |
Controlled Attenuation Parameter (CAP) at start and end of study Fibroscan (db/m)liver stiffness at start and end of study kPa,NAFLD fibrosis score at start, 3 months and end of study Calculation from parameters,Fibrosis-4 (FIB-4) Index at start, 3 months and end of study Calculation from parameters
|
| Sponsor/Collaborators: |
Ratchadaphiseksomphot Endowment Fund
|
| Gender: |
All
|
| Age: |
18 Years80 Years
|
| Phases: |
Phase 3
|
| Enrollment: |
--
|
| Study Type: |
Interventional
|
| Study Designs: |
Randomized
|
| Start Date: |
18/01/2019
|
| Completion Date: |
02/03/2020
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Thailand
|
| URL: |
www.thaiclinicaltrials.org/show/TCTR20190118008
|
